NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Contract Research Orgs » Charles River  1    
found files: 17
Charles River »23/03/2007 [Company watch]
Charles River commits to large expansion programme in Shanghai

Charles River Laboratories International, Inc. (NYSE:CRL) announced today the expansion of its global footprint in Asia as part of its strategy to support customers' research and development efforts in this rapidly growing market....   more»

Charles River »08/05/2007 [Company watch]
Charles River announces 1st Quarter 2007 results

see full report...   more»

Charles River »24/04/2007 [Company watch]
Charles River Laboratories Appoints Cheri Walker, Ph.D. as Corporate Senior Vice President, Corporate Development

Charles River Laboratories International, Inc. (NYSE: CRL) announced today the appointment of Cheri Walker, Ph.D. to the role of Corporate Senior Vice President, Corporate Development, effective April 24, 2007. Dr. Walker will be responsible for the Company's global corporate development function, directing all aspects of our merger, acquisition and strategic joint venture activities. She will also participate as an integral member in the strategic planning process of the Company. Prior to joining Charles River, Dr. Walker was Vice President, Mergers and Acquisitions for QIAGEN Sciences where she oversaw the corporate development of QIAGEN's North American life sciences tools and molecular diagnostics businesses. Previously, Dr. Walker held senior corporate development and operational positions at Invitrogen where she successfully executed acquisition and licensing transactions. James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories noted, "We are delighted to have Cheri join the Charles River team. Her depth of experience in life science transactions adds greater strength to our management team." Dr. Walker commented, "I have followed the growth of Charles River for several years and am very excited to be joining a dynamic and expanding company. Corporate Development will play an integral role in this growth and I am looking forward to being part of the team." Dr. Walker holds a doctorate in Human and Molecular Genetics from Baylor College of Medicine and a bachelor's degree in Biology from Swarthmore College....   more»

Charles River »10/06/2007 [Company watch]
Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd,

Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd, a Shanghai company that, like Charles River, provides pre-clinical CRO (Contract Research Organization) services. As one of the top two U.S. CROs, the menu of Charles River offerings are somewhat larger than BioExplorer's, although these will be expanded to meet the stated goal of supporting its customers’ needs, from drug discovery through proof of concept on a global basis....   more»

Charles River »22/10/2007 [Company watch]
Charles River expansion in China

1. Joint venture with Bioexplorer (Bioexplorer was set up in January 2005, a preclinical contract research company, its main customer includes Lily, Roche and Pfizer) was signed on March 2007. 2. Transaction completed on June 15 2007. 2. The joint venture company will be known as Charles River Laboratories Preclinical Services – China, which Charles River will be the majority owner. 3. Company plan- Phase One l 6000 square meter Pre-existing shell; l 38 study rooms; l 17 non-rodent rooms; l 21 rodent rooms; l Clean/dirty corridor; l Construction started in Oct.2007, and will be completed in May 2008; l Non-clinical pilot studies will begin in May 2008; l Open for business in July 2008; l Fully GLP validation will be finished in Aug.2008; l Receive AAALAC accredited in Feb.2009; l globally. It will build 120 studies rooms in 3-5 years. l Phase Two will meet the European animal welfare standard. l The final goal of service will be EMEA and US FDA GLP compliance. 5. Staff l CRL China have 45 staff now. They want to have 120 staff initially and then 225 in full. Senior staff will be sent to Montreal to train for 9-12 months. Currently there are 5 staffs in training in Montreal. l The Montreal experts will be sent to Shanghai to support this newly established lab. l Kewen also wants to collaborate with some big pharms to provide some training courses to the students (toxicology, phathology and veterinary) in Chinese University of Agriculture. 6. The existing IT system ensures earlier integration and data consistency. 7. Animal Resources: l Non Human Primates from Chinese supplier; 4. Company plan- Phase Two l This laboratory will become the second largest site of Charles River Dogs from Marshall-a joint venture company in Beijing; l SPF rodent import from Charles River Lab Japan; l Large rodent will come from Charles River Lab China Rodent facility which will be nearby and supply service throughout China. 8. Caging Have three Chinese suppliers making prototype at the moment. The one they choose will supply Charles River globally....   more»

Charles River »19/02/2008 [Company watch]
Charles River accelerates China plans; reports profit jump

Charles River Laboratories has reported another profit jump in its Q4 2007 financial results and has also stepped up its China plans as the demand for its preclinical services in the country are said to be "robust". In an analyst call related to its fourth quarter results, Jim Foster, company president, chairman and CEO said that it is now speeding up its facility expansion programme in China, where it is constructing a new 50,000 square foot laboratory, and is expecting to begin offering good laboratory practice (GLP) preclinical services from the country by the middle of this year instead of the first quarter of 2009....   more»

Charles River »15/10/2008 [Company watch]
Charles River Expands Global Footprint with Shanghai Facility Opening

New Facility Positions Company as Premier Preclinical CRO in China To support the growing demand from multinational pharmaceutical clients for outsourced drug development services, Charles River Laboratories International, Inc. (CRL) today announced the opening of its 60,000 square foot preclinical facility in Shanghai. The new China facility positions Charles River as the strategic partner of choice to fully support clients’ global drug development needs. “As our clients make their initial forays into China, we are creating a center of excellence that embodies global best practices alongside them,” said James C. Foster, President, Chairman and Chief Executive Officer of Charles River. “Our clients have come to appreciate and rely on the expertise Charles River brings to their drug development efforts, and the convenience of our facilities in close proximity. The same high standards of research, safety, humane care and good laboratory practices that globally distinguish Charles River are replicated in our Shanghai facility. Expanding into this arena is a marathon ― not a sprint ― and this facility marks the first step in our journey.” Creating a Center of Excellence in China Due to its large population and increasingly educated workforce, China is an emerging market for global drug development. As China continues to evolve as a center of innovation in research and development, the new facility will help foster this culture by helping multinationals as well as local biopharmaceutical organizations accelerate their drug development programs. The new facility is expected to provide Good Laboratory Practice (GLP) services in the first quarter of 2009. In addition, Charles River’s China facility will provide a wide range of services that are compliant with leading regulatory agencies including: * Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), * Canadian Council on Animal Care (CCAC), * China’s State Food and Drug Administration (SFDA), * Organization for Economic Cooperation and Development (OECD); and * U.S. Food and Drug Administration (FDA). “The rapidly growing economy and native science talent position China as an emerging powerhouse in the life sciences industry. Charles River is making a key strategic investment in local resources and staff to support the drug development programs of both multinational and native biopharmaceutical organizations in China,” said Kewen Jin, General Manager, Charles River Shanghai. An international group gathered to celebrate the opening of the facility including: academic leaders, senior government officials from China, and executives from multinational pharmaceutical companies and local biopharmaceutical organizations. The ceremony commenced with remarks from Charles River executives sharing ideas, plans and insights on the critical role China plays in drug development. Selecting a Strategic Partner In March 2007, Charles River announced a joint venture with Shanghai BioExplorer Co., Ltd., a Shanghai, China-based provider of preclinical services, to form Charles River Preclinical Services Greater China. The joint venture is majority owned and controlled by Charles River. Additional details of the joint venture are outlined in the press release “Charles River Expands Global Reach.”http://CharlesRiverChinaMarch2007...   more»

Charles River »07/11/2008 [Company watch]
Charles River Says CRO Business Slowing

Charles River Labs reduced its 2008 profit guidance by 3% because its CRO clients are delaying scheduled tests until next year....   more»

Charles River »23/02/2009 [Company watch]
Charles River Stock under Pressure

The stock has been under pressure lately due to investor concerns that drug companies will trim research and development expenses, and that industry consolidation would thin the company\'s customer base...   more»

Charles River »08/05/2009 [Company watch]
Charles River Laboratories Looking for 2nd China CRO Site

Charles River Laboratories said it is very pleased with its recently opened 50,000 square foot facility in China, and it is looking for a second location....   more»

Charles River
»28/07/2009 [Company watch]
Charles River Shanghai Achieves Accreditation Milestone

On the heels of its grand opening in October, the Charles River preclinical facility in Shanghai has been awarded Shanghai Laboratory Animal Commission (SLAC) Accreditation and full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)....   more»

Charles River
»08/10/2009 [Company watch]
Charles River Shanghai Facility Wins Animal Care Accreditations

Charles River reported that its year-old Shanghai CRO facility has received three accreditations from organisations protecting the care of laboratory animals: the Association for Assessment and Accreditation of Laboratory Animal Care ((AAALAC)), the Canadian Council on Animal Care (CCAC) and the Shanghai Laboratory Animal Commission (SLAC)....   more»

Charles River »03/11/2009 [Company watch]
Charles River Announces Third-Quarter 2009 Results

* Sales Decrease 13.1% to $297 Million...   more»

Charles River
»16/02/2010 [Company watch]
Charles River Labs Disappointed by Weak Demand for China Lab

Charles River Labs declared itself surprised at the low level of demand for its China CRO services. The company opened its lab in October 2008 and, almost immediately after, it was said to be looking for a second site....   more»

Charles River
»15/04/2010 [Company watch]
Charles River Shanghai preclinical facility receives Belgian GLP cert

Charles River Shanghai Receives OECD Certification. First preclinical contract research organization in China to receive certification...   more»

Charles River »26/04/2010 [Company watch]
Charles River and Wuxi Pharmatch to Combine, Creating the First Global CRO Offering Fully Integrated Early-Stage Drug Development Service

Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion....   more»

Charles River
»02/05/2010 [Company watch]
Charles River Goes Global With Largest Ever Foreign Takeover of Chinese Company

Clinical research group Charles River (CRL) is expanding its Asian footprint with a $1.6 billion purchase of WuXi PharmaTech (WX), a key player in China\'s thriving drug development market. It will be the largest foreign takeover of a Chinese company, according to Bloomberg....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.